Adicet Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	159.71	257.66	277.69	88.86	14.89	7.13	53.35
Short-Term Investments	0	0	0	10.28	51.79	100.99	0
Cash & Cash Equivalents	159.71	257.66	277.69	99.14	66.68	108.11	53.35
Cash Growth	-38.01%	-7.22%	180.10%	48.68%	-38.32%	102.65%	-
Receivables	0	0	0.19	0	0	0	0
Other Current Assets	2.56	3.38	4.56	1.2	-2.5	1.42	1.81
Total Current Assets	162.27	261.04	282.44	100.34	64.19	109.53	55.15
Property, Plant & Equipment	44.2	48.98	35	25.86	2.12	0.32	0.04
Long-Term Investments	0	0	0	0	10.59	0	0
Goodwill and Intangibles	0	19.46	19.46	20.09	0	0	0
Other Long-Term Assets	0.82	1.21	2.04	7.55	4.69	0.08	0
Total Long-Term Assets	45.02	69.65	56.5	53.5	17.4	0.41	0.04
Total Assets	207.3	330.69	338.94	153.84	81.59	109.94	55.19
Accounts Payable	2.63	4.4	3.26	1.55	1.05	2.99	1.52
Deferred Revenue	0	0	4.81	13.98	21.88	0	0
Current Debt	3.22	2.49	1.57	1.22	0	0	0
Other Current Liabilities	13.44	12.81	6.68	5.73	-8.07	2.73	3.99
Total Current Liabilities	19.29	19.71	16.32	22.48	14.87	5.72	5.5
Long-Term Debt	17.7	18.53	19.38	20.42	0	0	0
Other Long-Term Liabilities	0.13	0.11	0.12	1.11	13.01	0.02	0
Total Long-Term Liabilities	17.83	18.65	19.49	21.53	13.01	0.02	0
Total Liabilities	37.12	38.35	35.81	44.01	27.87	5.74	5.5
Total Debt	20.92	21.02	20.94	21.64	0	0	0
Debt Growth	-0.47%	0.38%	-3.21%	-	-	-	-
Retained Earnings	-380.77	-238.11	-168.32	-106.33	-69.65	-71.39	-33.78
Comprehensive Income	0	0	0	0.02	0.02	-0.04	0
Shareholders' Equity	170.18	292.34	303.13	109.83	-60.37	104.2	-31.93
Net Cash / Debt	138.79	236.63	256.75	77.5	66.68	108.11	53.35
Net Cash / Debt Growth	-41.35%	-7.84%	231.28%	16.23%	-38.32%	102.65%	-
Net Cash Per Share	3.22	5.76	8.30	10.59	31.17	55.53	93.14
Working Capital	142.99	241.33	266.12	77.86	49.32	103.82	49.65
Book Value Per Share	3.95	7.12	9.79	15.00	-28.22	53.52	-55.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).